

## OJSC "VEROPHARM" CONSOLIDATED INCOME STATEMENT

PROFIT FOR THE YEAR

FOR THE YEAR ENDED 31 DECEMBER 2011 (in millions of Russian Roubles) 2011 2010 **REVENUE** 6 348 5 395 COST OF SALES (2025)(1642)**GROSS PROFIT** 4 323 3 753\* SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2452)(2228)**OPERARING PROFIT** 1 871 1 525\* INTEREST INCOME 123 63 INTEREST EXPENSE (68)(119)FOREIGN CURRENCY EXCHANGE GAIN/(LOSS) 24 (6)**PROFIT BEFORE INCOME TAX** 1 950 1 463\* INCOME TAX EXPENSE (170)(214)\*

1 780

1 249\*

<sup>\*</sup> The consolidated financial statements for the year ended 31 December 2010 have been restated.



## OJSC "VEROPHARM"

CONSOLIDATED BALANCE SHEET AT 31 DECEMBER 2011

(in millions of Russian Roubles)	31.12.2011	31.12.2010
ASSETS		
NON-CURRENT ASSETS:		
Property, plant & equipment	1 386	844
Goodwill	287	287
Other intangible assets	87	74
Deferred tax assets, net	58	85
Total non-current assets	1 817	1 290
CURRENT ASSETS:		
Inventories	690	619*
Trade receivables	5 168	4 465
Other receivables and prepaid expenses	2 995	388
Loans receivable	27	175
Cash and cash equivalents	80	19
Total current assets	8 960	5 666
TOTAL ASSETS	10 778	6 956
EQUITY AND LIABILITIES		
EQUITY:		
Share capital	10	10
Reserves	1	1
Retained earnings	7 321	5 731*
Total equity	7 332	5 742
NON-CURRENT LIABILITIES:		
Long-term borrowings	158	169
Long-term portion of obligations under finance leases	0	6
Total non-current liabilities	158	175
CURRENT LIABILITIES:		
Short-term borrowings	325	295
Trade payables	1 653	276
Other payables and accrued expenses	1 020	252
Short-term portion of obligations under finance leases	6	8
Taxes payable	284	208
Total current liabilities	3 288	1 039
TOTAL LIABILITIES	3 446	1 214
TOTAL EQUITY AND LIABILITIES	10 778	6 956

 $<sup>^{</sup>st}$  The consolidated financial statements for the year ended 31 December 2010 have been restated.



## OJSC "VEROPHARM"

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2011

(in millions of Russian Roubles)	2011	2010
OPERATING ACTIVITIES:		
Profit for the year	1,780	1,249
Adjustments to profit for the year:		
Income tax	170	214
Interest expense	68	119
Interest income	(123)	(63)
Depreciation and amortization	136	129
Loss on disposal of other intangible assets and property, plant and equipment	2	11
Change in allowance for doubtful debts	2	(12)
Change in inventory obsolescence allowance	(19)	(28)
Foreign currency exchange (gain)/loss, net	(24)	6
Profit before movements in working capital	1,992	1,625
Movements in working capital:		
Increase in inventories	(41)	(222)
Increase in trade receivables	(708)	(522)
Decrease/(Increase) in other receivables and prepaid expenses	1,779	(144)
Decrease/(Increase) in trade payables	(1,902)	73
Increase in other payables and taxes payable	506	72
Cash generated from operations	1,626	882
Interest paid	(63)	(137)
Interest received	1	1
Income taxes paid	(368)	(162)
Net cash generated by operating activities	1,196	584
INVESTING ACTIVITIES:		
Purchase of property, plant, equipment	(669)	(171)
Proceeds from disposal of property, plant, equipment	3	5
Purchase of intangible assets	(40)	(42)
Proceeds from sale of short-term investments	-	200
Cash disposed with sale of subsidiary	(6)	-
Loans given to related parties	(387)	(124)
Proceeds from repayment of loans given	101	
Net cash used in investing activities	(998)	(132)
FINANCING ACTIVITIES:		
Dividends payment	(190)	-
Proceeds from borrowings	1,608	1,331
Repayment of borrowings and obligations under finance leases	(1,549)	(1,829)
Net cash used in financing activities	(131)	(498)
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	67	(46)
Effect of exchanges in balance of cash held in foreign currencies	(6)	-
CASH AND CASH EQUIVALENTS, beginning of period	19	65
CASH AND CASH EQUIVALENTS, end of period	80	19